Ovid Therapeutics Inc. (FRA:1OT)
Germany · Delayed Price · Currency is EUR 1.470
-0.030 (-2.00%)
Last updated: Dec 1, 2025, 8:10 AM CET
Ovid Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| 6.61 | 0.57 | 0.39 | 1.5 | 208.38 | 12.62 | Upgrade | |
Revenue Growth (YoY) | 945.89% | 44.39% | -73.91% | -99.28% | 1551.57% | - | Upgrade |
Gross Profit | 6.61 | 0.57 | 0.39 | 1.5 | 208.38 | 12.62 | Upgrade |
Selling, General & Admin | 20.76 | 23.88 | 29.59 | 32.43 | 37.23 | 30.63 | Upgrade |
Research & Development | 24.92 | 35.07 | 28.39 | 24.62 | 46.94 | 63.42 | Upgrade |
Operating Expenses | 45.68 | 58.95 | 57.97 | 57.05 | 84.17 | 94.05 | Upgrade |
Operating Income | -39.07 | -58.39 | -57.58 | -55.55 | 124.21 | -81.43 | Upgrade |
Interest & Investment Income | - | - | - | - | - | 0.4 | Upgrade |
Other Non Operating Income (Expenses) | 4.98 | 32.1 | 4.94 | 1.83 | -0.05 | - | Upgrade |
EBT Excluding Unusual Items | -36.18 | -26.28 | -52.64 | -53.71 | 124.16 | -81.04 | Upgrade |
Merger & Restructuring Charges | -1.8 | -3.5 | -1.7 | - | - | - | Upgrade |
Gain (Loss) on Sale of Investments | -0.15 | 3.35 | 2 | -0.45 | - | - | Upgrade |
Pretax Income | -36.33 | -26.43 | -52.34 | -54.17 | 124.16 | -81.04 | Upgrade |
Income Tax Expense | - | - | - | - | 1.33 | - | Upgrade |
Net Income | -36.33 | -26.43 | -52.34 | -54.17 | 122.83 | -81.04 | Upgrade |
Preferred Dividends & Other Adjustments | -0.46 | -0.46 | -0.91 | - | 3 | - | Upgrade |
Net Income to Common | -35.87 | -25.98 | -51.43 | -54.17 | 119.84 | -81.04 | Upgrade |
Shares Outstanding (Basic) | 71 | 71 | 71 | 70 | 67 | 58 | Upgrade |
Shares Outstanding (Diluted) | 71 | 71 | 71 | 70 | 68 | 58 | Upgrade |
Shares Change (YoY) | 0.35% | 0.46% | 0.22% | 3.46% | 16.45% | 49.05% | Upgrade |
EPS (Basic) | -0.50 | -0.37 | -0.73 | -0.77 | 1.78 | -1.39 | Upgrade |
EPS (Diluted) | -0.50 | -0.37 | -0.73 | -0.77 | 1.76 | -1.39 | Upgrade |
Free Cash Flow | -37.96 | -56.03 | -45.82 | -56.45 | 118.43 | -51.71 | Upgrade |
Free Cash Flow Per Share | -0.53 | -0.79 | -0.65 | -0.80 | 1.74 | -0.89 | Upgrade |
Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | Upgrade |
Operating Margin | -591.04% | -10315.37% | -14689.03% | -3696.44% | 59.61% | -645.40% | Upgrade |
Profit Margin | -542.69% | -4589.22% | -13119.39% | -3604.66% | 57.51% | -642.26% | Upgrade |
Free Cash Flow Margin | -574.22% | -9898.76% | -11689.03% | -3756.55% | 56.83% | -409.85% | Upgrade |
EBITDA | -38.65 | -57.77 | -57.01 | -55.04 | 124.45 | -81.12 | Upgrade |
EBITDA Margin | - | - | - | - | 59.72% | - | Upgrade |
D&A For EBITDA | 0.42 | 0.61 | 0.57 | 0.51 | 0.24 | 0.31 | Upgrade |
EBIT | -39.07 | -58.39 | -57.58 | -55.55 | 124.21 | -81.43 | Upgrade |
EBIT Margin | - | - | - | - | 59.61% | - | Upgrade |
Effective Tax Rate | - | - | - | - | 1.07% | - | Upgrade |
Revenue as Reported | 6.61 | 0.57 | 0.39 | 1.5 | 208.38 | 12.62 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.